Under construction – not a live service
Sign in
Taking people in CanadaPhase 2/3

Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells

Key facts

Where
Calgary, Hamilton, Montreal, Toronto, and Vancouver, CanadaSee the 5 sites
Phase
Phase 2/3

Where in Canada

  • University Of CalgaryCalgary, CanadaTaking people
  • HamiltonHamilton, CanadaNo longer taking part
  • CIUSSS de l'Est-de-l'Île-de-MontréalMontreal, CanadaTaking people
  • Princess Margaret Cancer CentreToronto, CanadaTaking people
  • VancouverVancouver, CanadaNo longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Celgene
Trial code
NCT03435796EU 2023-504201-36-00
Record updated
2 November 2026
Original description
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.Read full original descriptionShow less

Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells

This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous Celgene sponsored or Celgene alliance partner sponsored study.

Participants who received at least one infusion of GM T cells will be asked to enroll in this LTFU protocol upon either premature discontinuation from, or completion of the prior parent treatment protocol.

Inclusion: Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored, Juno Therapeutics, other affiliates of BMS, or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable; Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.

Exclusion: Not Applicable; Other protocol-defined inclusion/exclusion criteria apply.

ClinicalTrials.gov NCT03435796 · EU CTIS 2023-504201-36-00